Unexpected hematologic effects of biotherapeutics in nonclinical species and in humans

Toxicologic Pathology

Volumn 41, Issue 2, 2013, Pages 280-302

  Everds, Nancy E ^a   Tarrant, Jacqueline M ^b  

^a AMGEN INC   (United States)

^b GENENTECH INC   (United States)

Author keywords

anemia; biotherapeutics; hematotoxicity; immune mediated; monoclonal antibodies; neutropenia; thrombocytopenia

Indexed keywords

ABCIXIMAB; ADALIMUMAB; ALEMTUZUMAB; ALPHA2A INTERFERON; ALPHA2B INTERFERON; AME 133; BEVACIZUMAB; BLOSOZUMAB; CERTOLIZUMAB PEGOL; ECULIZUMAB; EFALIZUMAB; ERYTHROPOIETIN; ETANERCEPT; GAMMA INTERFERON; GOLIMUMAB; HEPARIN; INFLIXIMAB; INTERLEUKIN 10; MOXETUMOMAB PASUDOTOX; OCARATUZUMAB; OFATUMUMAB; OKT 3; OMALIZUMAB; PEGINTERFERON; RITUXIMAB; STREPTOKINASE; TOCILIZUMAB; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANEMIA; ARTICLE; BLOOD TOXICITY; CYTOKINE RELEASE; CYTOPENIA; ERYTHROPHAGOCYTOSIS; ERYTHROPOIESIS; HUMAN; HYPERSENSITIVITY; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; PURE RED CELL ANEMIA; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ANIMALS; ANTIBODIES, MONOCLONAL; BIOLOGICAL PRODUCTS; BIOLOGICAL THERAPY; HEMATOLOGIC DISEASES; HUMANS;

EID: 84875730536     PISSN: 01926233     EISSN: 15331601     Source Type: Journal    
DOI: 10.1177/0192623312467400     Document Type: Article

References (265)

1. Abdi E. A., Brien W., Venner P. M.. Auto-immune thrombocytopenia related to interferon therapy. Scand J Haematol. 1986 ; 36: 515-19
2. Abdi E. A., Venner P. M.. Immune thrombocytopenia after alpha-interferon therapy in patients with cancer. JAMA. 1986 ; 255: 1878-79
3. Abramowicz D., Crusiaux A., Goldman M.. Anaphylactic shock after retreatment with OKT3 monoclonal antibody. New Engl J Med. 1992 ; 327: 736
4. Abrams K., Yunusov M. Y., Slichter S., Moore P., Nelp W. B., Burstein S. A., McDonough S., Durack L., Storer B., Storb R., Gass M. J., Georges G., Nash R. A.. Recombinant human macrophage colony-stimulating factor-induced thrombocytopenia in dogs. Br J Haematol. 2003 ; 121: 614-22
5. Akamatsu S., Asazuma A., Kanamaru S., Takenawa J., Soeda A.. Immune thrombocytopenia during interferon-alfa therapy for renal cell carcinoma. Hinyokika Kiyo. 2006 ; 52: 789-92
6. Alvarez G. C., Gomez-Galicia D., Rodriguez-Fragoso L., Marina V. M., Dorantes L. C., Sanchez-Aleman M., Mendez-Sanchez N., Esparza J. R.. Danazol improves thrombocytopenia in HCV patients treated with peginterferon and ribavirin. Ann Hepatol. 2011 ; 10: 458-68
7. Ambrose L. R., Morel A. S., Warrens A. N.. Neutrophils express CD52 and exhibit complement-mediated lysis in the presence of alemtuzumab. Blood. 2009 ; 114: 3052-55
8. Anderson G. P., Anderson C. L.. Signal transduction by the platelet Fc receptor. Blood. 1990 ; 76: 1165-72
9. Andriani A., Bibas M., Callea V., De Renzo A., Chiurazzi F., Marceno R., Musto P., Rotoli B.. Autoimmune hemolytic anemia during alpha interferon treatment in nine patients with hematological diseases. Haematologica. 1996 ; 81: 258-60
10. Antonini M. G., Babudieri S., Maida I., Baiguera C., Zanini B., Fenu L., Dettori G., Manno D., Mura M. S., Carosi G., Puoti M.. Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin. Infection. 2008 ; 36: 250-5
11. Araki D., Fujii H., Matsumura M., Yamagishi M., Yachie A., Kawano M.. Etanercept-induced lupus accompanied by hemophagocytic syndrome. Intern Med. 2011 ; 50: 1843-48
12. Arimura K., Arima N., Ohtsubo H., Matsushita K., Kukita T., Ayukawa T., Kuroki T., Tei C.. Severe autoimmune thrombocytopenic purpura during interferon-alpha therapy for chronic myelogenous leukemia. Acta haematologica. 2004 ; 112: 217-18
13. Aster R. H. Platelets. Burlington, MA: Elsevier ; 2007: 887-902.
14. Aster R. H.. Adverse drug reactions affecting blood cells. Handbook Exp Pharmacol. 2010 ;: 57-76
15. Aster R. H., Bougie D. W.. Drug-induced immune thrombocytopenia. New Engl J Med. 2007 ; 357: 580-87
16. Baert F., Noman M., Vermeire S., Van Assche, G. D'Haens G., HCarbonez A., Rutgeerts P.. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. New Engl J Med. 2003 ; 348: 601-608
17. Baker G. R., Levin J.. Transient thrombocytopenia produced by administration of macrophage colony-stimulating factor: Investigations of the mechanism. Blood. 1998 ; 91: 89-99
18. Basser R. L., O'Flaherty E., Green M., Edmonds M., Nichol J., Menchaca D. M., Cohen B., Begley C. G.. Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor. Blood. 2002 ; 99: 2599-602
19. Baudouin V., Crusiaux A., Haddad E., Schandene L., Goldman M., Loirat C., Abramowicz D.. Anaphylactic shock caused by immunoglobulin E sensitization after retreatment with the chimeric anti-interleukin-2 receptor monoclonal antibody basiliximab. Transplantation. 2003 ; 76: 459-63
20. Baxley A., Akhtari M.. Hematologic toxicities associated with intravenous immunoglobulin therapy. Int Immunopharm. 2011 ; 11: 1663-67
21. Bello C., Sotomayor E. M.. Monoclonal antibodies for B-cell lymphomas: Rituximab and beyond. Hematology Am Soc Hematol Educ Program. 2007 ;: 233-42
22. Berkowitz S. D., Harrington R. A., Rund M. M., Tcheng J. E.. Acute profound thrombocytopenia after C7E3 Fab (abciximab) therapy. Circulation. 1997 ; 95: 809-13
23. Birmingham D. J., Hebert L. A., Shen X. P., Higgins P., Yeh C. G., Creasey A. A.. Effects of immune complex formation and complement activation on circulating platelets in the primate. Clin Immunol. 1999 ; 91: 99-105
24. Blake-Haskins J. A., Lechleider R. J., Kreitman R. J.. Thrombotic microangiopathy with targeted cancer agents. Clin Canc Res. 2011 ; 17: 5858-66
25. Boumpas D. T., Furie R., Manzi S., Illei G. G., Wallace D. J., Balow J. E., Vaishnaw A.. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum. 2003 ; 48: 719-27
26. Bremmer M. S., Bremmer S. F., Baig-Lewis S., Simpson E. L.. Are biologics safe in the treatment of atopic dermatitis? A review with a focus on immediate hypersensitivity reactions. J Am Acad Dermatol. 2009 ; 61: 666-76
27. Broxmeyer H. E., Lu L., Platzer E., Feit C., Juliano L., Rubin B. Y.. Comparative analysis of the influences of human gamma, alpha and beta interferons on human multipotential (CFU-GEMM), erythroid (BFU-E) and granulocyte-macrophage (CFU-GM) progenitor cells. J Immunol. 1983 ; 131: 1300-5
28. Brunasso A. M., Massone C.. Thrombocytopenia associated with the use of anti-tumor necrosis factor-alpha agents for psoriasis. J Am Acad Dermatol. 2009 ; 60: 781-85
29. Bugelski P. J., Achuthanandam R., Capocasale R. J., Treacy G., Bouman-Thio E.. Monoclonal antibody-induced cytokine-release syndrome. Expet Rev Clin Immunol. 2009 ; 5: 499-521
30. Bugelski P. J., Treacy G.. Predictive power of preclinical studies in animals for the immunogenicity of recombinant therapeutic proteins in humans. Curr Opin Mol Therapeut. 2004 ; 6: 10-16
31. Calogiuri G., Ventura M. T., Mason L., Valacca A., Buquicchio R., Cassano N., Vena G. A.. Hypersensitivity reactions to last generation chimeric, humanized [correction of umanized] and human recombinant monoclonal antibodies for therapeutic use. Curr Pharm Des. 2008 ; 14: 2883-91
32. Campath-1H (alemtuzumab) Pharmacology/Toxicology Review (2001). Accessed April 14, 2012. http://www.accessdata.fda.gov/drugsatfda-docs/nda/2000/103948- 0000-Campath-PharmTox.pdf.
33. Cancer Therapy Evaluation Program (2012). Accessed October 9, 2012. http://ctep.cancer.gov/protocolDevelopment/electronic-applications/ctc. htm#ctc-40.
34. Caramaschi P., Bambara L. M., Pieropan S., Tinazzi I., Volpe A., Biasi D.. Anti-TNFalpha blockers, autoantibodies and autoimmune diseases. Joint Bone Spine. 2009 ; 76: 333-42
35. Carney P. H., Ollom C. L.. Infusion reactions triggered by monoclonal antibodies treating solid tumors. J Infusion Nurs. 2008 ; 31: 74-83
36. Cartron G., Dacheux L., Salles G., Solal-Celigny P., Bardos P., Colombat P., Watier H.. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood. 2002 ; 99: 754-58
37. Cathomas R., von Moos R.. Severe drug-induced thrombocytopenia after treatment with trastuzumab but not with lapatinib. Ann Oncol. 2009 ; 20: 1606-607
38. Chaiwatanatorn K., Lee N., Grigg A., Filshie R., Firkin F.. Delayed-onset neutropenia associated with rituximab therapy. Br J Haematol. 2003 ; 121: 913-18
39. Cheifetz A., Smedley M., Martin S., Reiter M., Leone G., Mayer L., Plevy S.. The incidence and management of infusion reactions to infliximab: A large center experience. Am J Gastroenterol. 2003 ; 98: 1315-24
40. Chen M., Holland M. J., Mir M. R., Wong M. G., Kelley B. P., Grim K. D., Bhuchar S. S., Hsu S.. Frequency of thrombocytopenia in psoriasis patients treated with tumor necrosis factor-a inhibitors. J Drugs Dermatol. 2011 ; 10: 280-84
41. Chong B. H.. Heparin-induced thrombocytopenia. Br J Haematol. 1995 ; 89: 431-39
42. Chung C. H.. Managing premedications and the risk for reactions to infusional monoclonal antibody therapy. Oncologist. 2008 ; 13: 725-32
43. Chung C. H., Mirakhur B., Chan E., Le Q. T., Berlin J., Morse M., Murphy B. A., Satinover S. M., Hosen J., Mauro D., Slebos R. J., Zhou Q., Gold D., Hatley T., Hicklin D. J., Platts-Mills T. A.. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. New Engl J Med. 2008 ; 358: 1109-17
44. Cimzia (certolizumab pegol) label (2010). Accessed April 14, 2012. http://www.accessdata.fda.gov/drugsatfda-docs/label/2010/125160s111lbl.pdf.
45. Clemetson K. J., Clemetson J. M.. Platelet Receptors. Platelets. 2007 ;: 117-43
46. Corren J., Casale T. B., Lanier B., Buhl R., Holgate S., Jimenez P.. Safety and tolerability of omalizumab. Clin Exp All. 2009 ; 39: 788-97
47. Cotroneo T. M., Colby L. A., Bergin I. L.. Hemophagocytic syndrome in a pancytopenic simian retrovirus-infected male rhesus macaque (Macaca mulatta). Vet Pathol. 2011 ; 48: 1138-43
48. Couch J. A., Martin B., Smyczek T., Ye W., Peale P., Chan S., Ge N., Lau S., Hall L., Sun M., Bou-Reslan H., Barck K., Williams S., Tarrant J., Wakshull E., Carano R., Danilenko D. 2010 :
49. Cowgill L. D., James K. M., Levy J. K., Browne J. K., Miller A., Lobingier R. T., Egrie J. C.. Use of recombinant human erythropoietin for management of anemia in dogs and cats with renal failure. J Am Vet Med Assoc. 1998 ; 212: 521-28
50. Cox L. S.. How safe are the biologicals in treating asthma and rhinitis?. Allergy Asthma Clin Immunol. 2009 ; 5: 4
51. Cuker A.. Toxicities of the thrombopoietic growth factors. Semin Hematol. 2010 ; 47: 289-98
52. Cuker A., Coles A.J., Sullivan H., Fox E., Goldberg M., Oyuela P., Purvis A., Beardsley D.S., Margolin D.H.. A distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis. Blood. 2011 ; 118: 6299-305
53. Cunningham M. J., Silberstein L. E. Hematology Basic Concepts and Practice. Hoffman H. Benz E. J. Shattil S. J. Furie B. Cohen H. J. Siberstein L. E. McGlave P., ed. Philadelphia, PA: Elsevier Science ; 2005: 787-830.
54. Curtis B. R., Swyers J., Divgi A., McFarland J. G., Aster R. H.. Thrombocytopenia after second exposure to abciximab is caused by antibodies that recognize abciximab-coated platelets. Blood. 2002 ; 99: 2054-59
55. Daguet A., Watier H.. 2nd Charles Richet et Jules Hericourt workshop: Therapeutic antibodies and anaphylaxis; May 31-June 1, 2011, Tours, France. mAbs. 2011 ; 3: 417-21
56. Danese S., Fiocchi C.. Platelet activation and the CD40/CD40 ligand pathway: mechanisms and implications for human disease. Crit Rev Immunol. 2005 ; 25: 103-21
57. Davies K. A., Hird V., Stewart S., Sivolapenko G. B., Jose P., Epenetos A. A., Walport M. J.. A study of in vivo immune complex formation and clearance in man. J Immunol. 1990 ; 144: 4613-20
58. Davies R., Galloway J. B., Watson K. D., Lunt M., Symmons D. P., Hyrich K. L.. Venous thrombotic events are not increased in patients with rheumatoid arthritis treated with anti-TNF therapy: Results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2011 ; 70: 1831-34
59. Del Conde I., Cruz M. A., Zhang H., Lopez J. A., Afshar-Kharghan V.. Platelet activation leads to activation and propagation of the complement system. Journal Exp Med. 2005 ; 201: 871-79
60. Demirturk N., Cevik F., Demirdal T., Aykin N., Aslan V.. Autoimmune thrombocytopenia induced by PEG-IFN-alpha plus ribavirin in hepatitis C. Platelets. 2006 ; 17: 340-43
61. Dery J. P., Braden G. A., Lincoff A. M., Kereiakes D. J., Browne K., Little T., George B. S., Sane D. C., Cines D. B., Effron M. B., Mascelli M. A., Langrall M. A., Damaraju L., Barnathan E. S., Tcheng J. E.. Final results of the ReoPro readministration registry. Am J Cardiol. 2004 ; 93: 979-84
62. Desai S. B., Furst D. E.. Problems encountered during anti-tumour necrosis factor therapy. Best Pract Res Clin Rheumatol. 2006 ; 20: 757-90
63. Dhand S., Bahrain H.. Rituximab-induced severe acute thrombocytopenia: A case report and review of literature. Canc Investig. 2008 ; 26: 913-15
64. Dhir V., Fort M., Mahmood A., Higbee R., Warren W., Narayanan P., Wittman V.. A predictive biomimetic model of cytokine release induced by TGN1412 and other therapeutic monoclonal antibodies. J Immunotoxicol. 2012 ; 9: 34-42
65. Dietrich W., Spath P., Zuhlsdorf M., Dalichau H., Kirchhoff P. G., Kuppe H., Preiss D. U., Mayer G.. Anaphylactic reactions to aprotinin reexposure in cardiac surgery: Relation to antiaprotinin immunoglobulin G and E antibodies. Anesthesiol. 2001 ; 95: 64-71
66. Dillman R. O.. Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy. Cancer Metastasis Rev. 1999 ; 18: 465-71
67. Dinauer M. C., Coates T. D. Hematology Basic Concepts and Practice. Hoffman H. Benz E. J. Shattil S. J. Furie B. Cohen H. J. Siberstein L. E. McGlave P., ed. Philadelphia, PA: Elsevier Science ; 2005: 693-708.
68. Dixit R., Boelsterli U. A.. Healthy animals and animal models of human disease(s) in safety assessment of human pharmaceuticals, including therapeutic antibodies. Drug Discov Today. 2007 ; 12: 336-42
69. Dourakis S. P., Deutsch M., Hadziyannis S. J.. Immune thrombocytopenia and alpha-interferon therapy. J Hepatol. 1996 ; 25: 972-75
70. Drudi F., Gianni L., Fantini M., Ravaioli A.. Trastuzumab-related thrombocytopenia: Always a self-limiting complication?. Ann Oncol. 2010 ; 21: 668-69
71. Dunleavy K., Hakim F., Kim H. K., Janik J. E., Grant N., Nakayama T., White T., Wright G., Kwak L., Gress R., Tosato G., Wilson W. H.. B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis. Blood. 2005 ; 106: 795-802
72. Durante-Mangoni E., Iardino P., Utili R., Adinolfi L. E., Ruggiero G.. Defective synthesis of granulocyte-colony stimulating factor in pegylated interferon-alpha treated chronic hepatitis C patients with declining leukocyte counts. Antivir Ther. 2006 ; 11: 637-40
73. Eckardt K. U., Casadevall N.. Pure red-cell aplasia due to anti-erythropoietin antibodies. Nephrol Dial Transplant. 2003 ; 18: 865-69
74. Elefsiniotis I. S., Pantazis K. D., Fotos N. V., Moulakakis A., Mavrogiannis C.. Late onset autoimmune thrombocytopenia associated with pegylated interferon-alpha-2b plus ribavirin treatment for chronic hepatitis C. J Gastroenterol Hepatol. 2006 ; 21: 622-23
75. Elimelakh M., Dayton V., Park K. S., Gruessner A. C., Sutherland D., Howe R. B., Reding M. T., Eastlund T., van Burik J. A., Singleton T. P., Gruessner R. W., Key N. S.. Red cell aplasia and autoimmune hemolytic anemia following immunosuppression with alemtuzumab, mycophenolate, and daclizumab in pancreas transplant recipients. Haematologica. 2007 ; 92: 1029-36
76. Elter T., Hallek M., Montillo M.. Alemtuzumab: What is the secret to safe therapy?. Clin Adv Hematol Oncol. 2011 ; 9: 364-73
77. Enblad G., Hagberg H., Erlanson M., Lundin J., MacDonald A. P., Repp R., Schetelig J., Seipelt G., Osterborg A.. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy- refractory peripheral T-cell lymphomas. Blood. 2004 ; 103: 2920-24
78. Enomoto M., Yamane T., Hino M., Ohnishi M., Tamori A., Kawada N.. Platelet-associated IgG for the diagnosis of immune thrombocytopaenic purpura during peginterferon alpha and ribavirin treatment for chronic hepatitis C. Liver Inter. 2008 ; 28: 1314-15
79. Eremina V., Jefferson J. A., Kowalewska J., Hochster H., Haas M., Weisstuch J., Richardson C., Kopp J. B., Kabir M. G., Backx P. H., Gerber H. P., Ferrara N., Barisoni L., Alpers C. E., Quaggin S. E.. VEGF inhibition and renal thrombotic microangiopathy. New Eng J Med. 2008 ; 358: 1129-36
80. Ernstoff M. S., Kirkwood J. M.. Changes in the bone marrow of cancer patients treated with recombinant interferon alpha-2. Am J Med. 1984 ; 76: 593-96
81. Everds N., Li N., Bailey K., Fort M., Stevenson R., Jawando R., Salyers K., Jawa V., Narayanan P., Stevens E., He C., Nguyen N.P., Tran S., Doyle N., Poitout-Belissent F., Jolette J., Xu C., Sprugel K. Toxicol Pathol. 2013 :
82. Feldman D. R., Baum M. S., Ginsberg M. S., Hassoun H., Flombaum C. D., Velasco S., Fischer P., Ronnen E., Ishill N., Patil S., Motzer R. J.. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009 ; 27: 1432-9
83. Findlay L., Eastwood D., Ball C., Robinson C. J., Bird C., Wadhwa M., Thorpe S. J., Thorpe R., Stebbings R., Poole S.. Comparison of novel methods for predicting the risk of pro-inflammatory clinical infusion reactions during monoclonal antibody therapy. J Immunol Meth. 2011 ; 371: 134-42
84. Fitzgerald D. J., Catella F., Roy L., FitzGerald G. A.. Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction. Circulation. 1988 ; 77: 142-50
85. Blood. :
86. Francolla K. A., Altman A., Sylvester F. A.. Hemophagocytic syndrome in an adolescent with Crohn disease receiving azathioprine and infliximab. J Pediatr Gastroenterol Nutr. 2008 ; 47: 193-95
87. Fujii H., Kitada T., Yamada T., Sakaguchi H., Seki S., Hino M.. Life-threatening severe immune thrombocytopenia during alpha-interferon therapy for chronic hepatitis C. Hepato-gastroenterology. 2003 ; 50: 841-42
88. Fukuno K., Tsurumi H., Ando N., Kanemura N., Goto H., Tanabashi S., Okamoto K., Moriwaki H.. Late-onset neutropenia in patients treated with rituximab for non-Hodgkin's lymphoma. Int J Hematol. 2006 ; 84: 242-47
89. Galbraith W. M., Hobson W. C., Giclas P. C., Schechter P. J., Agrawal S.. Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey. Antisense Res Dev. 1994 ; 4: 201-206
90. Garnick M. B., O'Reilly R. J.. Clinical promise of new hematopoietic growth factors: M-CSF, IL-3, IL-6. Hematol Oncol Clin N Am. 1989 ; 3: 495-509
91. Garratty G., Petz L. D.. Direct antiglobulin test negative autoimmune haemolytic anaemia associated with fludarabine/cyclophosphamide/rituximab therapy. Br J Haematol. 2007 ; 139: 622-23
92. Gerloni V., Pontikaki I., Gattinara M., Fantini F.. Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients. Ann Rheumatic Dis. 2008 ; 67: 1145-52
93. Gibbs S. D., Westerman D. A., McCormack C., Seymour J. F., Miles Prince H.. Severe and prolonged myeloid haematopoietic toxicity with myelodysplastic features following alemtuzumab therapy in patients with peripheral T-cell lymphoproliferative disorders. Bri J Haematol. 2005 ; 130: 87-91
94. Giezen T. J., Mantel-Teeuwisse A. K., Meyboom R. H., Straus S. M., Leufkens H. G., Egberts T. C.. Mapping the safety profile of biologicals: A disproportionality analysis using the WHO adverse drug reaction database, VigiBase. Drug Saf. 2010 ; 33: 865-78
95. Gilleece M. H., Dexter T. M.. Effect of Campath-1H antibody on human hematopoietic progenitors in vitro. Blood. 1993 ; 82: 807-12
96. Goldenberg D. M., Morschhauser F., Wegener W. A.. Veltuzumab (humanized anti-CD20 monoclonal antibody): Characterization, current clinical results, and future prospects. Leuk Lymphoma. 2010 ; 51: 747-55
97. Golding A., Rosen A., Petri M., Akhter E., Andrade F.. Interferon-alpha regulates the dynamic balance between human activated regulatory and effector T cells: Implications for antiviral and autoimmune responses. Immunology. 2010 ; 131: 107-17
98. Goldsmith J. C., Lollar P., Hoak J. C.. Massive fatal pulmonary emboli with fibrinolytic therapy. Circulation. 1981 ; 64: 1068-69
99. Greinacher A.. Heparin-induced thrombocytopenia. J Thromb Haemost. 2009 ; 7 (Suppl 1). 9-12
100. Greinacher A., Potzsch B., Amiral J., Dummel V., Eichner A., Mueller-Eckhardt C.. Heparin-associated thrombocytopenia: Isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb Haemostasis. 1994 ; 71: 247-51
101. Gribble E. J., Sivakumar P. V., Ponce R. A., Hughes S. D.. Toxicity as a result of immunostimulation by biologics. Expet Opin Drug Metabol Toxicol. 2007 ; 3: 209-34
102. Hall R. L., Everds N. E. Principles and Methods of Toxicology. Hayes A., ed. 2007: 1317-58.
103. Hansel T. T., Kropshofer H., Singer T., Mitchell J. A., George A. J.. The safety and side effects of monoclonal antibodies. Nat Rev. Drug Discov. 2010 ; 9: 325-38
104. Haroon M., Daly M., Harney S.. Re-challenge with Etanercept in patients with Etanercept-induced Neutropenia. Clin Rheumatol. 2012 ; 31: 151-55
105. Hastings R., Ding T., Butt S., Gadsby K., Zhang W., Moots R. J., Deighton C.. Neutropenia in patients receiving anti-tumor necrosis factor therapy. Arthritis Care Res (Hoboken). 2010 ; 62: 764-9
106. Hatfield M., Meyer T., Meyer J., Robles-Carrillo L., Francis J. L., Amirkhosravi A.. Contribution of surface localization to platelet activation by CD154 antibodies and introduction of a novel approach for studying immune complex activity. Thromb Res. 2011 ; 127: 571-5
107. Hedin H., Richter W.. Pathomechanisms of dextran-induced anaphylactoid/anaphylactic reactions in man. Int Arch Allergy Appl Immunol. 1982 ; 68: 122-26
108. Hedin H., Smedegard G.. Complement profiles in monkeys subjected to aggregate (immune complex) anaphylaxis, and following injection of soluble and particulate polysaccharides. Int Arch Allergy Appl Immunol. 1979 ; 60: 286-94
109. Hellerstedt B., Ahmed A.. Delayed-type hypersensitivity reaction or serum sickness after rituximab treatment. Ann Oncol ESMO. 2003 ; 14: 1792
110. Henry S. P., Beattie G., Yeh G., Chappel A., Giclas P., Mortari A., Jagels M. A., Kornbrust D. J., Levin A. A.. Complement activation is responsible for acute toxicities in rhesus monkeys treated with a phosphorothioate oligodeoxynucleotide. Int Immunopharmacol. 2002 ; 2: 1657-66
111. Herzyk D. J., Bugelski P. J., Hart T. K., Wier P. J.. Preclinical safety of recombinant human interleukin-18. Toxic Pathol. 2003 ; 31: 554-61
112. Hostetler S. G., Zirwas M., Bechtel M. A.. Efalizumab-associated thrombocytopenia. J Am Acad Dermatol. 2007 ; 57: 707-10
113. Huhn R. D., Radwanski E., Gallo J., Affrime M. B., Sabo R., Gonyo G., Monge A., Cutler D. L.. Pharmacodynamics of subcutaneous recombinant human interleukin-10 in healthy volunteers. Clin Pharmacol Therapeut. 1997 ; 62: 171-80
114. Huhn R. D., Radwanski E., O'Connell S. M., Sturgill M. G., Clarke L., Cody R. P., Affrime M. B., Cutler D. L.. Pharmacokinetics and immunomodulatory properties of intravenously administered recombinant human interleukin-10 in healthy volunteers. Blood. 1996 ; 87: 699-705
115. Hurwitz N., Probst A., Zufferey G., Tichelli A., Pless M., Kappos L., Speck B., Gratwohl A.. Fatal vascular leak syndrome with extensive hemorrhage, peripheral neuropathy and reactive erythrophagocytosis: An unusual complication of recombinant IL-3 therapy. Leuk Lymphoma. 1996 ; 20: 337-40
116. May 1997
117. Ide K., Setoguchi-Mukai A., Nakagawa T., Uetsuka K., Nakayama H., Fujino Y., Ohno K., Tsujimoto H.. Disseminated histiocytic sarcoma with excessive hemophagocytosis in a cat. J Vet Med Sci. 2009 ; 71: 817-20
118. Janka G. E.. Hemophagocytic syndromes. Blood Rev. 2007 ; 21: 245-53
119. Jara Sanchez C., Olier Garate C., Garcia-Donas Jimenez J., Penalver Parraga J.. Drug-induced thrombocytopenia induced by trastuzumab: A special challenge in a curable disease. Ann Oncology. 2009 ; 20: 1607-608
120. Johnson C. W., Nachtman J. P., Cimprich R. E., Moon H. L., Mills S. E., Beckendorf J., Levine B. S., Long R. C., Fuller G. B., Losos G., Provencher A., Stoll R.E. Clinical and histopathological effects of M-CSF in laboratory animals. Int Rev Exp Pathol. 1993 ; 34 Pt A: 189-204
121. Jourdan E., Topart D., Richard B., Jourdan J., Sotto A.. Severe autoimmune hemolytic anemia following rituximab therapy in a patient with a lymphoproliferative disorder. Leuk Lymphoma. 2003 ; 44: 889-90
122. Kang S. P., Saif M. W.. Infusion-related and hypersensitivity reactions of monoclonal antibodies used to treat colorectal cancer - identification, prevention, and management. J Supportive Oncol. 2007 ; 5: 451-57
123. Kawai T., Andrews D., Colvin R. B., Sachs D. H., Cosimi A. B.. Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat Med. 2000 ; 6: 114
124. Kessary-Shoham H., Levy Y., Shoenfeld Y., Lorber M., Gershon H.. In vivo administration of intravenous immunoglobulin (IVIg) can lead to enhanced erythrocyte sequestration. J Autoimmun. 1999 ; 13: 129-35
125. Keystone E. C.. Tumor necrosis factor-alpha blockade in the treatment of rheumatoid arthritis. Rheumatic Dis Clin N Am. 2001 ; 27: 427-43
126. Kilickap S., Abali H., Celik I.. Bevacizumab, bleeding, thrombosis, and warfarin. J Clin Oncol. 2003 ; 21: 3542
127. Kim S. R., Imoto S., Kudo M., Nakajima T., Ando K., Mita K., Fukuda K., Hong H. S., Lee Y. H., Nakashima K., Shoji I., Nagano-Fujii M., Hotta H., Hayashi Y.. Autoimmune thrombocytopenic purpura during pegylated interferon alpha treatment for chronic hepatitis C. Intern Med. 2010 ; 49: 1119-22
128. Kinsell L. W., Kopeloff L. M., Zwemer R. L., Kopeloff N.. Blood constituents during anaphylactic shock in the monkey. J Immunol. 1941 ; 42: 35-50
129. Kitano K., Gibo Y., Kamijo A., Furuta K., Oguchi S., Joshita S., Takahashi Y., Ishida F., Matsumoto M., Uemura M., Fujimura Y.. Thrombotic thrombocytopenic purpura associated with pegylated-interferon alpha-2a by an ADAMTS13 inhibitor in a patient with chronic hepatitis C. Haematologica. 2006 ; 91: ECR34
130. Klastersky J.. Adverse effects of the humanized antibodies used as cancer therapeutics. Curr Opin Oncol. 2006 ; 18: 316-20
131. Kopeloff N., Kopeloff L. M.. Blood platelets in anaphylaxis. J. Immunol. 1941 ; 40: 471
132. Korswagen L. A., Bartelds G. M., Krieckaert C. L., Turkstra F., Nurmohamed M. T., van Schaardenburg D., Wijbrandts C. A., Tak P. P., Lems W. F., Dijkmans B. A., van Vugt R. M., Wolbink G. J.. Venous and arterial thromboembolic events in adalimumab-treated patients with antiadalimumab antibodies: A case series and cohort study. Arthritis Rheum. 2011 ; 63: 877-83
133. Kowdley K. V.. Hematologic side effects of interferon and ribavirin therapy. J Clin Gastroenterol. 2005 ; 39: S3-8
134. Krishnan R. S., Hsu S.. Serum sickness due to infliximab in a patient with psoriasis. J Drugs Dermatol. 2004 ; 3: 305-8
135. Kuruvilla J., Leitch H. A., Vickars L. M., Galbraith P. F., Li C. H., Al-Saab S., Naiman S. C.. Aplastic anemia following administration of a tumor necrosis factor-alpha inhibitor. Eur J Haematol. 2003 ; 71: 396-98
136. Kut C., Mac Gabhann F., Popel A. S.. Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer. Bri J Canc. 2007 ; 97: 978-85
137. Kuter D. J., Begley C. G.. Recombinant human thrombopoietin: Basic biology and evaluation of clinical studies. Blood. 2002 ; 100: 3457-69
138. Lajus S., Clofent-Sanchez G., Jais C., Coste P., Nurden P., Nurden A.. Thrombocytopenia after abciximab use results from different mechanisms. Thromb Haemostasis. 2010 ; 103: 651-61
139. Lambotte O., Gelu-Simeon M., Maigne G., Kotb R., Buffet C., Delfraissy J. F., Goujard C.. Pegylated interferon alpha-2a-associated life-threatening Evans' syndrome in a patient with chronic hepatitis C. J Infection. 2005 ; 51: e113-5
140. Leal T., Robins H. I.. Bevacizumab induced reversible thrombocytopenia in a patient with recurrent high-grade glioma: A case report. Canc Chemother Pharmacol. 2010 ; 65: 399-401
141. Leikola J., Koistinen J., Lehtinen M., Virolainen M.. IgA-induced anaphylactic transfusion reactions: A report of four cases. Blood. 1973 ; 42: 111-9
142. Lemery S. J., Zhang J., Rothmann M. D., Yang J., Earp J., Zhao H., McDougal A., Pilaro A., Chiang R., Gootenberg J. E., Keegan P., Pazdur R.. U.S. Food and Drug Administration approval: Ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab. Clin Canc Res. 2010 ; 16: 4331-38
143. Lenz H. J.. Management and preparedness for infusion and hypersensitivity reactions. Oncologist. 2007 ; 12: 601-609
144. Li J., Yang C., Xia Y., Bertino A., Glaspy J., Roberts M., Kuter D. J.. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood. 2001 ; 98: 3241-48
145. Li L., Han D. K., Lu J.. Interferon-alpha induced severe thrombocytopenia: a case report and review of the literature. World J Gastroenterol. 2010 ; 16: 1414-17
146. Li S. C., Chen Y. C., Evens A. M., Lee C. C., Liao H. F., Yu C. C., Tung Y. T., Su Y. C.. Rituximab-induced late-onset neutropenia in newly diagnosed B-cell lymphoma correlates with Fc receptor FcgammaRIIIa 158(V/F) polymorphism. Am J Hematol. 2010b ; 85: 810-12
147. Ljungstrom K. G., Revenas B., Smedegard G., Hedin H., Richter W., Saldeen T.. Histopathological lung changes in immune complex mediated anaphylactic shock in humans elicited by dextran. Forensic Sci Int. 1988 ; 38: 251-58
148. Lundin J., Hagberg H., Repp R., Cavallin-Stahl E., Freden S., Juliusson G., Rosenblad E., Tjonnfjord G., Wiklund T., Osterborg A.. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood. 2003 ; 101: 4267-72
149. Maggi E., Vultaggio A., Matucci A.. Acute infusion reactions induced by monoclonal antibody therapy. Expet Rev Clin Immunol. 2011 ; 7: 55-63
150. Mantzourani M., Gogas H., Katsandris A., Meletis J.. Severe thrombocytopenia related to trastuzumab infusion. Med Sci Mon Int Med J Exp Clin Res. 2011 ; 17: CS85-87
151. Martin P. L., Fisher D., Glass W., O'Neil K., Das A., Martin E. C., Li L.. Preclinical safety and pharmacology of an anti-human interleukin-13 monoclonal antibody in normal macaques and in macaques with allergic asthma. Int J Toxicol. 2008 ; 27: 351-58
152. Mayer L., Young Y.. Infusion reactions and their management. Gastroenterol Clin N Am. 2006 ; 35: 857-66
153. McKoy J. M., Stonecash R. E., Cournoyer D., Rossert J., Nissenson A. R., Raisch D. W., Casadevall N., Bennett C. L.. Epoetin-associated pure red cell aplasia: Past, present, and future considerations. Transfusion. 2008 ; 48: 1754-62
154. McLaughlin P., Talpaz M., Quesada J. R., Saleem A., Barlogie B., Gutterman J. U.. Immune thrombocytopenia following alpha-interferon therapy in patients with cancer. JAMA. 1985 ; 254: 1353-4
155. McRedmond J. P., Harriott P., Walker B., Fitzgerald D. J.. Streptokinase-induced platelet activation involves antistreptokinase antibodies and cleavage of protease-activated receptor-1. Blood. 2000 ; 95: 1301-8
156. Medeiros B. C., Seligman P. A., Everson G. T., Forman L. M.. Possible autoimmune thrombocytopenia associated with pegylated interferon-alpha2a plus ribavarin treatment for hepatitis C. J Clin Gastroenterol. 2004 ; 38: 84-6
157. Meyer T., Robles-Carrillo L., Robson T., Langer F., Desai H., Davila M., Amaya M., Francis J. L., Amirkhosravi A.. Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2A transgenic mice. J Thromb Haemostasis. 2009 ; 7: 171-81
158. Michelmann I., Bockmann D., Nurnberger W., Eckhof-Donovan S., Burdach S., Gobel U.. Thrombocytopenia and complement activation under recombinant TNF alpha/IFN gamma therapy in man. Ann Hematol. 1997 ; 74: 179-84
159. Milner J. D., Orekov T., Ward J. M., Cheng L., Torres-Velez F., Junttila I., Sun G., Buller M., Morris S. C., Finkelman F. D., Paul W. E.. Sustained IL-4 exposure leads to a novel pathway for hemophagocytosis, inflammation, and tissue macrophage accumulation. Blood. 2010 ; 116: 2476-83
160. Mirabet M., Barrabes J. A., Quiroga A., Garcia-Dorado D.. Platelet pro-aggregatory effects of CD40L monoclonal antibody. Mol Immunol. 2008 ; 45: 937-44
161. Mitoma H., Horiuchi T., Tsukamoto H., Tamimoto Y., Kimoto Y., Uchino A., To K., Harashima S., Hatta N., Harada M.. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: Comparison among infliximab, etanercept, and adalimumab. Arthritis Rheum. 2008 ; 58: 1248-57
162. Morschhauser F., Leonard J. P., Fayad L., Coiffier B., Petillon M. O., Coleman M., Schuster S. J., Dyer M. J., Horne H., Teoh N., Wegener W. A., Goldenberg D. M.. Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results. J Clin Oncol. 2009 ; 27: 3346-53
163. Morschhauser F., Marlton P., Vitolo U., Linden O., Seymour J. F., Crump M., Coiffier B., Foa R., Wassner E., Burger H. U., Brennan B., Mendila M.. Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma. Ann Oncol. 2010 ; 21: 1870-76
164. Munn D. H., Garnick M. B., Cheung N. K.. Effects of parenteral recombinant human macrophage colony-stimulating factor on monocyte number, phenotype, and antitumor cytotoxicity in nonhuman primates. Blood. 1990 ; 75: 2042-48
165. Nash R. A., Burstein S. A., Storb R., Yang W., Abrams K., Appelbaum F. R., Boone T., Deeg H. J., Durack L. D., Schuening F. G.. Thrombocytopenia in dogs induced by granulocyte-macrophage colony-stimulating factor: Increased destruction of circulating platelets. Blood. 1995 ; 86: 1765-75
166. Nesbitt A., Fossati G., Bergin M., Stephens P., Stephens S., Foulkes R., Brown D., Robinson M., Bourne T.. Mechanism of action of certolizumab pegol (CDP870): In vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis. 2007 ; 13: 1323-32
167. Newman P. M., Chong B. H.. Heparin-induced thrombocytopenia: New evidence for the dynamic binding of purified anti-PF4-heparin antibodies to platelets and the resultant platelet activation. Blood. 2000 ; 96: 182-7
168. Nurnberger W., Michelmann I., Eckhof-Donovan S., Bockmann D., Petrik K., Gobel G., Burdach S., Gobel U.. Platelet consumption and activation of the complement system induced by infusion of rTNF alpha and rIFN gamma. A N Y Acad Sci. 1994 ; 714: 291-92
169. O'Neil B. H., Allen R., Spigel D. R., Stinchcombe T. E., Moore D. T., Berlin J. D., Goldberg R. M.. High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history. J Clin Oncol. 2007 ; 25: 3644-48
170. Olson H., Betton G., Robinson D., Thomas K., Monro A., Kolaja G., Lilly P., Sanders J., Sipes G., Bracken W., Dorato M., Van Deun K., Smith P., Berger B., Heller A.. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul Toxicol Pharmacol. 2000 ; 32: 56-67
171. Padmore R. F.. Hemolysis upon intravenous immunoglobulin transfusion. Transfus Apheresis Sci. 2012 ; 46: 93-6
172. Parikh O., Neave F., Palmieri C.. Severe thrombocytopenia induced by a single infusion of trastuzumab. Clin Breast Canc. 2008 ; 8: 285-6
173. Patel D. D., Goldberg R. M.. Cetuximab-associated infusion reactions: Pathology and management. Oncology (Williston Park). 2006 ; 20: 1373-82
174. Patel S., Patel M., Din I., Reddy C. V., Kassotis J.. Profound thrombocytopenia associated with tirofiban: Case report and review of literature. Angiology. 2005 ; 56: 351-5
175. Pathare S. K., Heycock C., Hamilton J.. TNFalpha blocker-induced thrombocytopenia. Rheumatology (Oxford). 2006 ; 45: 1313-4
176. PEG-INTRON (Peg-IFNα-2b) Toxicologists Review (2004). Accessed October 10, 2012. http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/ HowDrugsareDevelopedandApproved/ApprovalApplications/ TherapeuticBiologicApplications/ucm094485.pdf.
177. Pegasys (Peg-IFNα-2a) Preclinical Review (2009). Accessed October 10, 2012. http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/ HowDrugsareDevelopedandApproved/ApprovalApplications/ TherapeuticBiologicApplications/ucm094465.pdf.
178. Peginterferon alpha 2a, Scientific Discussion (2005). Accessed October 12, 2012. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Scientific- Discussion/human/000395/WC500039192.pdf.
179. Pessina A., Albella B., Bayo M., Bueren J., Brantom P., Casati S., Croera C., Gagliardi G., Foti P., Parchment R., Parent-Massin D., Schoeters G., Sibiril Y., Van Den Heuvel R., Gribaldo L.. Application of the CFU-GM assay to predict acute drug-induced neutropenia: an international blind trial to validate a prediction model for the maximum tolerated dose (MTD) of myelosuppressive xenobiotics. Toxicol Sci. 2003 ; 75: 355-67
180. Pessina A., Albella B., Bayo M., Bueren J., Brantom P., Casati S., Croera C., Parchment R., Parent-Massin D., Schoeters G., Sibiri Y., Van Den Heuvel R., Gribaldo L.. In vitro tests for haematotoxicity: Prediction of drug-induced myelosuppression by the CFU-GM assay. ATLA. 2002 ; 30 (Suppl 2). 75-9
181. Peterson J. E., Zurakowski D., Italiano J. E., Michel L. V., Fox L., Klement G. L., Folkman J.. Normal ranges of angiogenesis regulatory proteins in human platelets. Am J Hematol. 2010 ; 85: 487-93
182. Petitpain N., Gambier N., Wahl D., Chary-Valckenaere I., Loeuille D., Gillet P.. Arterial and venous thromboembolic events during anti-TNF therapy: A study of 85 spontaneous reports in the period 2000-2006. Biomed Mater. 2009 ; 19: 355-64
183. Pichler W. J.. Adverse side-effects to biological agents. Allergy. 2006 ; 61: 912-20
184. Pisoni R., Ruggenenti P., Remuzzi G.. Drug-induced thrombotic microangiopathy: Incidence, prevention and management. Drug Saf. 2001 ; 24: 491-501
185. Ponce R., Abad L., Amaravadi L., Gelzleichter T., Gore E., Green J., Gupta S., Herzyk D., Hurst C., Ivens I. A., Kawabata T., Maier C., Mounho B., Rup B., Shankar G., Smith H., Thomas P., Wierda D.. Immunogenicity of biologically-derived therapeutics: Assessment and interpretation of nonclinical safety studies. Regul Toxicol Pharmacol. 2009 ; 54: 164-82
186. Proctor L., Renzulli B., Warren S., Brecher M. E.. Transfusion Medicine Illustrated. Monoclonal antibody-stimulated serum sickness. Transfusion. 2004 ; 44: 955
187. Radegran K., Drugge U., Olsson P.. Pulmonary venoconstriction by induced platelet aggregation. Acta Anaesthesiol Scand. 1974 ; 18: 243-47
188. Radegran K., McAslan C.. Circulatory and ventilatory effects of induced platelet aggregation and their inhibition by acetylsalicylic acid. Acta Anaesthesiol Scand. 1972 ; 16: 76-84
189. Ram R., Bonstein L., Gafter-Gvili A., Ben-Bassat I., Shpilberg O., Raanani P.. Rituximab-associated acute thrombocytopenia: An under-diagnosed phenomenon. Am J Hematol. 2009 ; 84: 247-50
190. Ramos-Casals M., Garcia-Carrasco M., Lopez-Medrano F., Trejo O., Forns X., Lopez-Guillermo A., Munoz C., Ingelmo M., Font J.. Severe autoimmune cytopenias in treatment-naive hepatitis C virus infection: Clinical description of 35 cases. Medicine. 2003 ; 82: 87-96
191. Rao J., Mascarenhas D. A.. Successful use of eptifibatide as an adjunct to coronary stenting in a patient with abciximab-associated acute profound thrombocytopenia. J Invasive Cardiol. 2001 ; 13: 471-3
192. Raptiva prescribing information (2005). Accessed 26 April 2012, 2012. www.gene.com/gene/products/information/pdf/raptiva-prescribing.pdf.
193. Reddy M. S., Carmody T. J., Kereiakes D. J.. Severe delayed thrombocytopenia associated with abciximab (ReoPro) therapy. Catheter Cardiovas Inter. 2001 ; 52: 486-8
194. Revenas B., Smedegard G., Saldeen T.. The pulmonary reaction in aggregate anaphylaxis in the monkey. Acta Chirurgica Scand Suppl. 1980 ; 499: 161-70
195. Review of CMC for Xolair (2003). Accessed 26 April 2012. http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/ HowDrugsareDevelopedandApproved/ApprovalApplications/ TherapeuticBiologicApplications/ucm113460.pdf.
196. Risitano A. M., Notaro R., Marando L., Serio B., Ranaldi D., Seneca E., Ricci P., Alfinito F., Camera A., Gianfaldoni G., Amendola A., Boschetti C., Di Bona E., Fratellanza G., Barbano F., Rodeghiero F., Zanella A., Iori A. P., Selleri C., Luzzatto L., Rotoli B.. Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab. Blood. 2009 ; 113: 4094-100
197. Rituxin (rituximab) Preclinical and Clinical Pharmacology Review (1997). Accessed April 14, 2012. http://www.fda.gov/downloads/Drugs/ DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/ TherapeuticBiologicApplications/ucm113334.pdf.
198. Robles-Carrillo L., Meyer T., Hatfield M., Desai H., Davila M., Langer F., Amaya M., Garber E., Francis J. L., Hsu Y. M., Amirkhosravi A.. Anti-CD40L immune complexes potently activate platelets in vitro and cause thrombosis in FCGR2A transgenic mice. J Immunol. 2010 ; 185: 1577-83
199. Rudmann D. G., Page T. J., Vahle J. L., Chouinard L., Haile S., Poitout F., Baskin G., Lambert A. J., Walker P., Glazier G., Awori M., Bernier L.. Rat-specific decreases in platelet count caused by a humanized monoclonal antibody against sclerostin. Toxicolo Sci. 2012 ; 125: 586-94
200. Russell K. E. 2010 ). Platelet kinetics and laboratory evaluaton of thrombocytopenia. In Schalm's Veterinary Hematology (WeissD. J., ed.), 6th Ed., pp. 576-85. Wiley-Blackwell, Ames, IA. Weiss D. J., ed. Ames, IA: Wiley-Blackwell ; 2010: 576-85.
201. Sacchi S., Kantarjian H., O'Brien S., Cohen P. R., Pierce S., Talpaz M.. Immune-mediated and unusual complications during interferon alfa therapy in chronic myelogenous leukemia. J Clin Oncol. 1995 ; 13: 2401-7
202. Sagir A., Wettstein M., Heintges T., Haussinger D.. Autoimmune thrombocytopenia induced by PEG-IFN-alpha2b plus ribavirin in hepatitis C. Dig Dis Sci. 2002 ; 47: 562-63
203. Said S. M., Hahn J., Schleyer E., Muller M., Fiedler G. M., Buerke M., Prondzinsky R.. Glycoprotein IIb/IIIa inhibitor-induced thrombocytopenia: Diagnosis and treatment. Clin Res Cardiol. 2007 ; 96: 61-9
204. Salar A., Bessa X., Muniz E., Monfort D., Besses C., Andreu M.. Infliximab and adalimumab-induced thrombocytopenia in a woman with colonic Crohn's disease. Gut. 2007 ; 56: 1169-70
205. Santostefano M. J., Kirchner J., Vissinga C., Fort M., Lear S., Pan W. J., Prince P. J., Hensley K. M., Tran D., Rock D., Vargas H. M., Narayanan P. K., Jawando R., Rees W., Reindel J. F., Reynhardt K., Everds N.. Off-target platelet activation in macaques unique to a therapeutic monoclonal antibody. Toxicol Pathol. 2012 ;:
206. Sata M., Yano Y., Yoshiyama Y., Ide T., Kumashiro R., Suzuki H., Tanikawa K.. Mechanisms of thrombocytopenia induced by interferon therapy for chronic hepatitis B. J Gastroenterol. 1997 ; 32: 206-10
207. Scappaticci F. A., Skillings J. R., Holden S. N., Gerber H. P., Miller K., Kabbinavar F., Bergsland E., Ngai J., Holmgren E., Wang J., Hurwitz H.. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Nat Canc Inst. 2007 ; 99: 1232-39
208. Schuler W., Bigaud M., Brinkmann V., Di Padova F., Geisse S., Gram H., Hungerford V., Kleuser B., Kristofic C., Menninger K., Tees R., Wieczorek G., Wilt C., Wioland C., Zurini M.. Efficacy and safety of ABI793, a novel human anti-human CD154 monoclonal antibody, in cynomolgus monkey renal allotransplantation. Transplantation. 2004 ; 77: 717-26
209. Schutz F. A., Jardim D. L., Je Y., Choueiri T. K.. Haematologic toxicities associated with the addition of bevacizumab in cancer patients. Eur J Cancer. 2011 ; 47: 1161-74
210. Sevastianos V. A., Deutsch M., Dourakis S. P., Manesis E. K.. Pegylated interferon-2b-associated autoimmune thrombocytopenia in a patient with chronic hepatitis C. Am J Gastroenterol. 2003 ; 98: 706-707
211. Shantsila E., Lip G. Y., Chong B. H.. Heparin-induced thrombocytopenia. A contemporary clinical approach to diagnosis and management. Chest. 2009 ; 135: 1651-64
212. Smedegard G., Revenas B., Arfors K. E.. Anaphylaxis in the monkey: hemodynamics and blood flow distribution. Acta Physiol Scand. 1979 ; 106: 191-98
213. Smedegard G., Revenas B., Saldeen T.. Aggregate anaphylaxis in the monkey: Haematological and histological findings. Int Arch Allergy Appli Immunol. 1980 ; 61: 117-24
214. Sosman J. A., Verma A., Moss S., Sorokin P., Blend M., Bradlow B., Chachlani N., Cutler D., Sabo R., Nelson M., Bruno E., Gustin D., Viana M., Hoffman R.. Interleukin 10-induced thrombocytopenia in normal healthy adult volunteers: Evidence for decreased platelet production. Bri J Haemato. 2000 ; 111: 104-11
215. Soza A., Everhart J. E., Ghany M. G., Doo E., Heller T., Promrat K., Park Y., Liang T. J., Hoofnagle J. H.. Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. Hepatology. 2002 ; 36: 1273-9
216. Stamatopoulos K., Papadaki T., Pontikoglou C., Athanasiadou I., Stavroyianni N., Bux J., Batsis I., Pyrovolaki K., Paterakis G., Anagnostou D., Anagnostopoulos A., Papadaki H. A.. Lymphocyte subpopulation imbalances, bone marrow hematopoiesis and histopathology in rituximab-treated lymphoma patients with late-onset neutropenia. Leukemia. 2008 ; 22: 1446-49
217. Storage S. S., Agrawal H., Furst D. E.. Description of the efficacy and safety of three new biologics in the treatment of rheumatoid arthritis. Korean J Intern Med. 2010 ; 25: 1-17
218. Stromberg P. C., Vogtsberger L. M., Marsh L. R., Wilson F. D.. Pathology of the mononuclear cell leukemia of Fischer rats. II. Hematology. Vet Pathol. 1983 ; 20: 709-17
219. Suntharalingam G., Perry M. R., Ward S., Brett S. J., Castello-Cortes A., Brunner M. D., Panoskaltsis N.. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. New Engl J Med. 2006 ; 355: 1018-28
220. Szebeni J.. Complement activation-related pseudoallergy: A new class of drug-induced acute immune toxicity. Toxicology. 2005 ; 216: 106-21
221. Szebeni J., Alving C. R., Rosivall L., Bunger R., Baranyi L., Bedocs P., Toth M., Barenholz Y.. Animal models of complement-mediated hypersensitivity reactions to liposomes and other lipid-based nanoparticles. J Liposome Res. 2007 ; 17: 107-17
222. Tanaka K. A., Katori N., Kelly A. B., Kotze H., Marzec U., Hanson S. R.. In vivo platelet redistribution and acute transient thrombocytopenia after eptifibatide injection in baboons. Thrombosis Res. 2005 ; 115: 79-87
223. Tanaka Y., Kurosaki M., Nishida N., Sugiyama M., Matsuura K., Sakamoto N., Enomoto N., Yatsuhashi H., Nishiguchi S., Hino K., Hige S., Itoh Y., Tanaka E., Mochida S., Honda M., Hiasa Y., Koike A., Sugauchi F., Kaneko S., Izumi N., Tokunaga K., Mizokami M.. Genome-wide association study identified ITPA/DDRGK1 variants reflecting thrombocytopenia in pegylated interferon and ribavirin therapy for chronic hepatitis C. Hum Mol Genet. 2011 ; 20: 3507-16
224. Tawara T., Hasegawa K., Sugiura Y., Harada K., Miura T., Hayashi S., Tahara T., Ishikawa M., Yoshida H., Kubo K., Ishida I., Kataoka S.. Complement activation plays a key role in antibody-induced infusion toxicity in monkeys and rats. J Immunol. 2008 ; 180: 2294-98
225. Tcheng J. E.. Clinical challenges of platelet glycoprotein IIb/IIIa receptor inhibitor therapy: Bleeding, reversal, thrombocytopenia, and retreatment. Am Heart J. 2000 ; 139: S38-45
226. Terrier B., Ittah M., Tourneur L., Louache F., Soumelis V., Lavie F., Casadevall N., Candon S., Hummel A., Mariette X., Buzyn A.. Late-onset neutropenia following rituximab results from a hematopoietic lineage competition due to an excessive BAFF-induced B-cell recovery. Haematologica. 2007 ; 92: e20-23
227. Tesfa D., Gelius T., Sander B., Kimby E., Fadeel B., Palmblad J., Hagglund H.. Late-onset neutropenia associated with rituximab therapy: Evidence for a maturation arrest at the (pro)myelocyte stage of granulopoiesis. Med Oncol. 2008 ; 25: 374-9
228. Tesfa D., Palmblad J.. Late-onset neutropenia following rituximab therapy: incidence, clinical features and possible mechanisms. Expet Rev Hematol. 2011 ; 4: 619-25
229. Thompson A. J., Clark P. J., Singh A., Ge D., Fellay J., Zhu M., Zhu Q., Urban T. J., Patel K., Tillmann H. L., Naggie S., Afdhal N. H., Jacobson I. M., Esteban R., Poordad F., Lawitz E. J., McCone J., Shiffman M. L., Galler G. W., King J. W., Kwo P. Y., Shianna K. V., Noviello S., Pedicone L. D., Brass C. A., Albrecht J. K., Sulkowski M. S., Goldstein D. B., McHutchison J. G., Muir A. J.. Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients. J Hepatol. 2012 ; 56: 313-19
230. Tobinai K., Ogura M., Kobayashi Y., Uchida T., Watanabe T., Oyama T., Maruyama D., Suzuki T., Mori M., Kasai M., Cronier D., Wooldridge J. E., Koshiji M.. Phase I study of LY2469298, an Fc-engineered humanized anti-CD20 antibody, in patients with relapsed or refractory follicular lymphoma. Canc Sci. 2011 ; 102: 432-38
231. Todd D. J., Helfgott S. M.. Serum sickness following treatment with rituximab. J Rheumatol. 2007 ; 34: 430-3
232. Tom W. L., Miller M. D., Hurley M. Y., Suneja T., Kudva G., Leonardi C. L., Obadiah J. M.. Efalizumab-induced autoimmune pancytopenia. Bri J Dermatol. 2006 ; 155: 1045-47
233. Tomer A., Stahl C. P., McClure H. M., Anderson D. C., Myers L. A., Liehl E., Winton E. F.. Effects of recombinant human granulocyte-macrophage colony-stimulating factor on platelet survival and activation using a nonhuman primate model. Exp Hematol. 1993 ; 21: 1577-82
234. Uetrecht J. P.. The role of leukocyte-generated reactive metabolites in the pathogenesis of idiosyncratic drug reactions. Drug Metab Rev. 1992 ; 24: 299-366
235. van der Laken C. J., Voskuyl A. E., Roos J. C., Stigter van Walsum M., de Groot E. R., Wolbink G., Dijkmans B. A., Aarden L. A.. Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis. Ann Rheumatic Dis. 2007 ; 66: 253-56
236. van Gils F. C., Mulder A. H., van den Bos C., Burger H., van Leen R. W., Wagemaker G.. Acute side effects of homologous interleukin-3 in rhesus monkeys. Am J Pathol. 1993 ; 143: 1621-33
237. Vaughan D. E., Van Houtte E., Declerck P. J., Collen D.. Streptokinase-induced platelet aggregation. Prevalence and mechanism. Circulation. 1991 ; 84: 84-91
238. Verheul H. M., Hoekman K., Luykx-de Bakker S., Eekman C. A., Folman C. C., Broxterman H. J., Pinedo H. M.. Platelet: Transporter of vascular endothelial growth factor. Clin Canc Res. 1997 ; 3: 2187-90
239. Verheul H. M., Lolkema M. P., Qian D. Z., Hilkes Y. H., Liapi E., Akkerman J. W., Pili R., Voest E. E.. Platelets take up the monoclonal antibody bevacizumab. Clin Canc Res. 2007 ; 13: 5341-47
240. Via C. S., Shustov A., Rus V., Lang T., Nguyen P., Finkelman F. D.. In vivo neutralization of TNF-alpha promotes humoral autoimmunity by preventing the induction of CTL. J Immunol. 2001 ; 167: 6821-26
241. Vidal F., Fontova R., Richart C.. Severe neutropenia and thrombocytopenia associated with infliximab. Ann Intern Med. 2003 ; 139: W - W63
242. Visentin G. P., Ford S. E., Scott J. P., Aster R. H.. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Investig. 1994 ; 93: 81-88
243. Visentin G. P., Liu C. Y.. Drug-induced thrombocytopenia. Hematol Oncol Clin N Am. 2007 ; 21: 685-96
244. Vitt C. R., Fidler J. M., Ando D., Zimmerman R. J., Aukerman S. L.. Antifungal activity of recombinant human macrophage colony-stimulating factor in models of acute and chronic candidiasis in the rat. J Infect Dis. 1994 ; 169: 369-74
245. Vogel W. H.. Infusion reactions: diagnosis, assessment, and management. Clin J Oncol Nurs. 2010 ; 14: E10-21
246. Wadenvik H., Kutti J., Ridell B., Revesz P., Jacobsson S., Magnusson B., Westin J., Vilen L.. The effect of alpha-interferon on bone marrow megakaryocytes and platelet production rate in essential thrombocythemia. Blood. 1991 ; 77: 2103-8
247. Waggie K.S., Holdren M.S., Byrnes-Blake K., Pedersen S., Ponce R., Hughes S., Miller D.M.. Preclinical safety, pharmacokinetics, and pharmacodynamics of recombinant human interleukin-21 in cynomolgus macaques (Macaca fascicularis). Int J Toxicol. 2012 ; 31: 303-16
248. Walenga J. M., Jeske W. P., Messmore H. L.. Mechanisms of venous and arterial thrombosis in heparin-induced thrombocytopenia. J Thromb Thrombolysis. 2000 ; 10 (Suppl 1). 13-20
249. Warkentin T. E., Kwon P.. Immune thrombocytopenia associated with efalizumab therapy for psoriasis. Ann Intern Med. 2005 ; 143: 761-3
250. Weiss D. J.. Hemophagocytic syndrome in dogs: 24 cases (1996-2005). J Am Vet Med Assoc. 2007 ; 230: 697-701
251. Weng W. K., Negrin R. S., Lavori P., Horning S. J.. Immunoglobulin G Fc receptor FcgammaRIIIa 158 V/F polymorphism correlates with rituximab-induced neutropenia after autologous transplantation in patients with non-Hodgkin's lymphoma. J Clin Oncol. 2010 ; 28: 279-84
252. Wenham C., Gadsby K., Deighton C.. Three significant cases of neutropenia with etanercept. Rheumatology (Oxford). 2008 ; 47: 376-7
253. Wierda W. G., Kipps T. J., Mayer J., Stilgenbauer S., Williams C. D., Hellmann A., Robak T., Furman R. R., Hillmen P., Trneny M., Dyer M. J., Padmanabhan S., Piotrowska M., Kozak T., Chan G., Davis R., Losic N., Wilms J., Russell C. A., Osterborg A.. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol. 2010 ; 28: 1749-55
254. Williams R. J., Clarke E., Blair A., Evely R., Hale G., Waldmann H., Brookes S., Pamphilon D. H.. Impact on T-cell depletion and CD34+ cell recovery using humanised CD52 monoclonal antibody (CAMPATH-1H) in BM and PSBC collections; comparison with CAMPATH-1M and CAMPATH-1G. Cytotherapy. 2000 ; 2: 5-14
255. Wolbink G. J., Vis M., Lems W., Voskuyl A. E., de Groot E., Nurmohamed M. T., Stapel S., Tak P. P., Aarden L., Dijkmans B.. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum. 2006 ; 54: 711-5
256. Worth R. G., Chien C. D., Chien P., Reilly M. P., McKenzie S. E., Schreiber A. D.. Platelet FcgammaRIIA binds and internalizes IgG-containing complexes. Exp Hematol. 2006 ; 34: 1490-95
257. Wright H. L., Chikura B., Bucknall R. C., Moots R. J., Edwards S. W.. Changes in expression of membrane TNF, NF-{kappa}B activation and neutrophil apoptosis during active and resolved inflammation. Ann Rheum Dis. 2011 ; 70: 537-43
258. Wu S. J., Luo J., O'Neil K. T., Kang J., Lacy E. R., Canziani G., Baker A., Huang M., Tang Q. M., Raju T. S., Jacobs S. A., Teplyakov A., Gilliland G. L., Feng Y.. Structure-based engineering of a monoclonal antibody for improved solubility. Protein Eng Des Sel. 2010 ; 23: 643-51
259. Xolair: European Public Assessment Report (2012). Accessed August 8, 2012. http://www.emea.europa.eu/ema/index.jsp?curl=pages/medicines/human/ medicines/000606/human-med-001162.sjsp.
260. Yamane A., Nakamura T., Suzuki H., Ito M., Ohnishi Y., Ikeda Y., Miyakawa Y.. Interferon-alpha 2b-induced thrombocytopenia is caused by inhibition of platelet production but not proliferation and endomitosis in human megakaryocytes. Blood. 2008 ; 112: 542-50
261. Yang J. F., Kao Y. H., Dai C. Y., Huang J. F., Hsieh M. Y., Lin Z. Y., Chen S. C., Wang L. Y., Chuang W. L., Yu M. L.. Comparison of adverse effects related to pegylated interferon-based therapy for patients with chronic hepatitis B and chronic hepatitis C in Taiwan. Hepatol Int. 2010 ; 4: 732-40
262. Zamkoff K. W., Hudson J., Groves E. S., Childs A., Konrad M., Rudolph A. R.. A phase I trial of recombinant human macrophage colony-stimulating factor by rapid intravenous infusion in patients with refractory malignancy. J Immunotherapy. 1992 ; 11: 103-10
263. Zelster D., Fusman R., Chapman J., Rotstein R., Shapira I., Elkayam O., Eldor A., Arber N., Berliner S.. Increased leukocyte aggregation induced by gamma-globulin: A clue to the presence of pseudoleukopenia. Am J Med Sci. 2000 ; 320: 177-82
264. Zoller E. E., Lykens J. E., Terrell C. E., Aliberti J., Filipovich A. H., Henson P. M., Jordan M. B.. Hemophagocytosis causes a consumptive anemia of inflammation. J Exp Med. 2011 ; 208: 1203-14
265. Zuffa E., Vianelli N., Martinelli G., Tazzari P., Cavo M., Tura S.. Autoimmune mediated thrombocytopenia associated with the use of interferon-alpha in chronic myeloid leukemia. Haematologica. 1996 ; 81: 533-35